ImmuCell Corporation provided earnings guidance for first quarter ending March 31, 2023. For the period, the company expects to report reduced sales during the first quarter of 2023 and a large, increased backlog as of March 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.27 USD | -3.12% | +3.54% | +3.54% |
04-09 | Immucell Corporation Reports Unaudited Sales Results for the Three Months and Twelve Months Ended March 31, 2024 | CI |
04-02 | ImmuCell Shares Fall After $20 Million Mixed Securities Shelf Filing | MT |
1st Jan change | Capi. | |
---|---|---|
+3.54% | 41.23M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+45.09% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- ICCC Stock
- News ImmuCell Corporation
- Immucell Corporation Provides Earnings Guidance for First Quarter Ending March 31, 2023